We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Safety and Efficacy of I 0401 in the Treatment of Tibial Plateau Fractures Requiring Grafting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00409799
Recruitment Status : Completed
First Posted : December 11, 2006
Last Update Posted : March 16, 2012
Information provided by (Responsible Party):
Kuros Biosurgery AG

Brief Summary:
For certain tibial plateau fractures the bone is compressed due to the force acting on the tibia during the accident. The void provoked by the compression of the bone is filled with an appropriate filling material and the fracture is fixated. I 0401 is a new bone graft substitute that has shown capacities to promote bone-healing. This study will test the safety and efficacy of I 0401 in the treatment of patients with tibial plateau fractures requiring grafting.

Condition or disease Intervention/treatment Phase
Tibia Plateau Fractures Drug: I-0401 (a new bone graft substitute) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 208 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Controlled, Open-label (Dose-blinded), Multi-center, Dose-finding Study of the Safety and Efficacy of I-0401 in the Treatment of Patients With Fractures of the Tibial Plateau Requiring Grafting.
Study Start Date : November 2006
Actual Primary Completion Date : September 2011
Actual Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Experimental - high dose
Drug: I-0401 (a new bone graft substitute)
1 time application

Experimental: 2
Experimental - low dose
Drug: I-0401 (a new bone graft substitute)
1 time application

Active Comparator: 3
Drug: I-0401 (a new bone graft substitute)
1 time application

Primary Outcome Measures :
  1. Radiographic Images [ Time Frame: All Follow-Up Visits ]

Secondary Outcome Measures :
  1. Clinical assessments of the fracture site [ Time Frame: All Follow-Up Visits ]
  2. Blood parameters [ Time Frame: All Follow-Up Visits ]
  3. Vital signs [ Time Frame: At several Follow-Up visits ]
  4. Questionnaires of Life [ Time Frame: All Follow-Up Visits ]
  5. Pharmacoeconomic evaluation [ Time Frame: All Follow-Up Visits ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Radiological evidence of a tibial plateau fracture requiring grafting
  • Females of child-bearing potential must be willing to undergo a pregnancy test (urine) prior to treatment start (at screening).

Exclusion Criteria:

  • Concomitant ipsilateral fractures of the limb other than the fracture of the tibial plateau.
  • Active or past history of malignant tumor.
  • Evidence of systemic or localized infection at time of surgery.
  • Pregnant or lactating females.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00409799

Show Show 45 study locations
Sponsors and Collaborators
Kuros Biosurgery AG
Layout table for investigator information
Principal Investigator: Peter Messmer, MD Zurich University Hospital, Zurich, Switzerland
Layout table for additonal information
Responsible Party: Kuros Biosurgery AG
ClinicalTrials.gov Identifier: NCT00409799    
Other Study ID Numbers: CS I-040101/02
First Posted: December 11, 2006    Key Record Dates
Last Update Posted: March 16, 2012
Last Verified: March 2012
Keywords provided by Kuros Biosurgery AG:
Bone graft substitute
Promotion of bone healing
Additional relevant MeSH terms:
Layout table for MeSH terms
Fractures, Bone
Tibial Plateau Fractures
Wounds and Injuries
Knee Fractures
Tibial Fractures
Knee Injuries
Leg Injuries